Based on surveyor observation, record review and staff interview, it has been determined that the facility failed to follow the manufacturer's instructions when COVID-19 rapid testing residents, for 14 of 14 residents observed, Resident ID #'s 11, 24, 27, 38, 45, 62, 85, 315, 316, 355, 356, 357, 359, and 362. Findings are as follows: The Centers for Disease Control document titled, Guidance for SARS-CoV-2 Rapid Testing Performed in Point-of-Care Settings, updated on 4/4/2022, states in part: .During the test .When processing multiple specimens successively in batches, ensure proper timing for each specimen .as specified by the test manufacturer .After the test .Read and record results only within the amount of time specified in the manufacturer's instructions. …
F886 citations in Rhode Island
Infection Control Deficiencies
Perform COVID19 testing on residents and staff.
Data as of , released by CMS on October 8, 2026. Source: CMS Provider Data Catalog.
Against expectation — 2023
Rhode Island cites F886 more often than its own record predicts
2.41 times the share F886 takes of citations nationally.
Of every deficiency written in Rhode Island in 2023, this is the portion that was F886.
Each state is measured against its own expected share, not against other states.
In the surveyor’s words
What Rhode Island surveyors wrote
F886 findings written in Rhode Island, one from each severity band recorded here, most serious first.
Severity is as the surveyor wrote it. Some findings had already been corrected before the survey.
What else Rhode Island surveyors cite →
Deficiency Index is independent and is not affiliated with, endorsed by, or approved by CMS, Medicare, or any government agency. About this data · Report a correction